The US Food and Drug Administration (FDA) on Thursday approved the first medication for people with a severe type of non-alcoholic fatty liver disease.

Madrigal Pharmaceuticals’ Rezdiffra was shown to improve liver scarring in a clinical trial involving hundreds of people with non-alcoholic steatohepatitis (NASH), the worst form of the condition caused by a buildup of fat in the liver.

“Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage,” said the FDA’s Nikolay Nikolov.

“Today’s approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise.”

    • @Trollception
      link
      English
      88 months ago

      Obesity, diabetes or high triglycerides.

    • @autumn_rain
      link
      English
      1
      edit-2
      8 months ago

      Thyroid disorders cause high cholesterol and can cause non-alcoholic fatty liver disease because it’s unable to process cholesterol effectively. A person can have fatty liver and be active and thin, don’t eat sugar, junk food, drink, etc.

      Edit… also just because someone is taking thyroid medicine, the cholesterol issue doesn’t always resolve.